Aurora Cannabis Inc. has introduced its Daily Special™ brand to the German medical cannabis market, with the product becoming available to patients on December 19 2025 through pharmacies and telemedicine platforms nationwide. The brand centers on a sativa‑dominant cultivar derived from Gelonade × Biscotti, delivering THC levels of 21‑23 % and less than 1 % CBD, positioned as a high‑quality, affordable option for German patients.
The launch underscores Aurora’s strategy to deepen its footprint in Germany, the company’s fastest‑growing market. Leveraging EU GMP‑certified manufacturing and an established distribution network, Aurora can supply a consistent, pharmaceutical‑grade product that meets the country’s stringent regulatory standards. The Daily Special™ brand adds to Aurora’s existing IndiMed line, reinforcing its high‑margin medical cannabis portfolio in a jurisdiction that is projected to reach €1.0–1.3 billion by 2027.
Management highlighted the significance of the expansion, noting that “the launch of Daily Special in Germany is a clear demonstration of Aurora’s long‑term investment and leadership in one of the world’s most important medical cannabis markets and key region for the company.” The statement reflects Aurora’s confidence in capturing additional market share and strengthening patient choice in a competitive landscape where only three companies are licensed to grow medicinal cannabis.
Aurora’s Q2 fiscal 2026 results provide context for the launch. Net revenue rose 11 % year‑over‑year to $90.4 million, with global medical revenue up 15 % and international medical revenue up 22 %. Adjusted EBITDA increased 52 % to $15.4 million, indicating robust profitability and the capacity to support new product introductions.
The Daily Special™ launch is expected to broaden Aurora’s patient base, enhance its competitive positioning, and contribute to the company’s high‑margin growth strategy in regulated European markets. By offering a new, affordable option, Aurora aims to capture a larger share of Germany’s expanding medical cannabis market while reinforcing its reputation for quality and reliability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.